Across TCGA pan-cancer cohorts, MIR1912 RNA is linked to patient survival in 1 of 34 cancer types, making it the most broadly survival-associated MIR1912 data layer.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher MIR1912 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MIR1912 expression acts as an unfavorable survival marker.
STAD are the cancer types where MIR1912 RNA most reproducibly stratifies survival.